gatifloxacin has been researched along with Tuberculosis, Multidrug-Resistant in 15 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Tuberculosis, Multidrug-Resistant: Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0." | 5.36 | Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. ( Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N, 2010) |
| "Ineffectively treated tuberculosis (TB) is associated with substantial morbidity and mortality." | 2.53 | Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy. ( Corelli, F; Frosini, M; Saponara, S; Sgaragli, G, 2016) |
| "Gatifloxacin has a susceptible dose-dependent zone at MICs 0." | 1.48 | Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis. ( Ambrose, PG; Bendet, P; Bhavnani, SM; Deshpande, D; Gumbo, T; Gumusboga, M; Koeuth, T; McIlleron, H; Pasipanodya, JG; Smythe, W; Srivastava, S; Thwaites, G; Van Deun, A, 2018) |
| "To assess outcome and adverse drug events with a standardised 12-month regimen for MDR-TB among second-line drug naïve patients." | 1.42 | High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. ( Abena Foe, JL; Aït-Khaled, N; Kuaban, C; Noeske, J; Rieder, HL; Trébucq, A, 2015) |
| "The number of pulmonary tuberculosis (PTB) patients reported with resistance to first-line anti-tuberculosis drugs after a standardized retreatment regimen in Cameroon is increasing." | 1.38 | Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon. ( Abena Foe, JL; Fon, E; Noeske, J; Voelz, N, 2012) |
| "Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0." | 1.36 | Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. ( Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, YQ | 1 |
| Zhang, S | 1 |
| Zhao, F | 1 |
| Gao, C | 1 |
| Feng, LS | 1 |
| Lv, ZS | 1 |
| Xu, Z | 1 |
| Wu, X | 1 |
| Nie, Q | 1 |
| Tao, L | 1 |
| Li, Y | 1 |
| Chen, N | 1 |
| Chen, H | 2 |
| Zhou, Y | 1 |
| Wang, Y | 1 |
| Tang, Q | 1 |
| Wang, X | 1 |
| Huang, C | 1 |
| Yang, C | 1 |
| Van Deun, A | 7 |
| Decroo, T | 2 |
| Kuaban, C | 2 |
| Noeske, J | 3 |
| Piubello, A | 3 |
| Aung, KJM | 1 |
| Rieder, HL | 5 |
| Ngabonziza, JCS | 1 |
| Migambi, P | 1 |
| Niyigena, EB | 1 |
| Dusabe, T | 1 |
| Habimana, YM | 1 |
| Ushizimpumu, B | 1 |
| Mulders, W | 1 |
| Affolabi, D | 1 |
| Supply, P | 1 |
| de Jong, BC | 1 |
| Rigouts, L | 1 |
| Chiang, CY | 2 |
| Trébucq, A | 2 |
| Deshpande, D | 1 |
| Pasipanodya, JG | 1 |
| Srivastava, S | 1 |
| Bendet, P | 1 |
| Koeuth, T | 1 |
| Bhavnani, SM | 1 |
| Ambrose, PG | 1 |
| Smythe, W | 1 |
| McIlleron, H | 1 |
| Thwaites, G | 1 |
| Gumusboga, M | 1 |
| Gumbo, T | 1 |
| Lalloo, UG | 1 |
| Aung, KJ | 1 |
| Declercq, E | 1 |
| Sarker, MR | 1 |
| Das, PK | 1 |
| Hossain, MA | 1 |
| Harouna, SH | 1 |
| Souleymane, MB | 1 |
| Boukary, I | 1 |
| Morou, S | 1 |
| Daouda, M | 1 |
| Hanki, Y | 1 |
| Aït-Khaled, N | 1 |
| Abena Foe, JL | 2 |
| Sgaragli, G | 1 |
| Frosini, M | 1 |
| Saponara, S | 1 |
| Corelli, F | 1 |
| Poissy, J | 1 |
| Aubry, A | 1 |
| Fernandez, C | 1 |
| Lott, MC | 1 |
| Chauffour, A | 1 |
| Jarlier, V | 1 |
| Farinotti, R | 1 |
| Veziris, N | 1 |
| Voelz, N | 1 |
| Fon, E | 1 |
| Yadav, V | 1 |
| Deopujari, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB[NCT05278988] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-04-01 | Recruiting | ||
| Culture Free Diagnosis and Follow-up of Multidrug Resistant Tuberculosis Patients[NCT03303963] | 3,356 participants (Actual) | Observational | 2017-05-04 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for gatifloxacin and Tuberculosis, Multidrug-Resistant
| Article | Year |
|---|---|
Isoniazid derivatives and their anti-tubercular activity.
Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Isoniazid; Mycobacterium tuberculosis; Tuber | 2017 |
Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy.
Topics: Antitubercular Agents; Bacterial Proteins; Clinical Trials as Topic; Fluoroquinolones; Gatifloxacin; | 2016 |
13 other studies available for gatifloxacin and Tuberculosis, Multidrug-Resistant
| Article | Year |
|---|---|
High-dose gatifloxacin-based shorter treatment regimens for MDR/RR-TB.
Topics: Antitubercular Agents; Gatifloxacin; Humans; Isoniazid; Pyrazinamide; Treatment Outcome; Tuberculosi | 2022 |
Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bangladesh; Cameroon; Child; Drug | 2019 |
Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Clofazimine; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; | 2020 |
Should gatifloxacin be included in the model list of essential medicines?
Topics: Drugs, Essential; Gatifloxacin; Humans; Tuberculosis, Multidrug-Resistant; World Health Organization | 2018 |
Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
Topics: Antitubercular Agents; Gatifloxacin; Humans; Lung; Microbial Sensitivity Tests; Monte Carlo Method; | 2018 |
Short-course Bangladesh regimen for multidrug-resistant tuberculosis: a step in the right direction?
Topics: Anti-Bacterial Agents; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Tuberculosis, Multidrug | 2014 |
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bangladesh; Child; Clofazimine; Dose-Response Relati | 2014 |
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bangladesh; Child; Clofazimine; Dose-Response Relati | 2014 |
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bangladesh; Child; Clofazimine; Dose-Response Relati | 2014 |
Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bangladesh; Child; Clofazimine; Dose-Response Relati | 2014 |
High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses.
Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Clofazimine; Dose-Response Relationship, Drug | 2014 |
High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cameroon; Clofazimine; Cohort Studies; Confidence In | 2015 |
Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Bangladesh; Blood Glucose; Cameroon; Dose-Response Relationship, Drug; Fluoro | 2016 |
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
Topics: Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Enoxacin; Fluoroquinolones; Gatifloxacin; | 2010 |
Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon.
Topics: Adult; Antitubercular Agents; Cameroon; Drug Resistance, Multiple, Bacterial; Feasibility Studies; F | 2012 |
Gatifloxacin and dysglycemia in older adults.
Topics: Anti-Bacterial Agents; Fluoroquinolones; Gatifloxacin; Humans; Hyperglycemia; Hypoglycemia; Mortalit | 2006 |